Insilico Medicine completed a long-anticipated Hong Kong listing and simultaneously disclosed new internal small-molecule programs. The company raised proceeds after multiple attempts to go public, underscoring investor appetite for AI-enabled drug discovery plays. Insilico also published preclinical data on salt‑inducible kinase (SIK) inhibitors, expanding its pipeline beyond in silico hit finding to tangible chemistry series. For investors and partnering prospects, the combination of fresh capital and disclosed assets sharpens the company’s commercial and alliance opportunities.